News

 

11/28/17
Vir Biotechnology Appoints Herbert W. “Skip” Virgin Executive Vice President and Chief Scientific Officer

SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Herbert W. "Skip" Virgin, M.D., Ph.D., as Executive Vice President of Research and Chief Scientific Officer, effective January 1, 2018. Reporting to CEO George Scangos and joining Vir’s management team, Dr. Virgin will lead the company’s significant and growing R&D programs to transform the care of people with serious infectious diseases.

Read More

10/18/17
Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious Diseases

SAN FRANCISCO—Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALYN), and Visterra, Inc., as well as four leading academic research institutions. Together with the company’s internal research and development capabilities, these achievements provide the foundation on which Vir will pursue its mission of transforming the care of people with serious infectious diseases.  

Read More

01/05/17
Vir Biotechnology Launches to Cure, Treat, and Prevent Challenging Infectious Diseases Using Latest Advances in Immunology

SAN FRANCISCO—Vir Biotechnology, Inc. today announced it is launching to develop cures, treatments, and preventions for challenging infectious diseases, with former Biogen CEO George Scangos heading a team of scientific and industry leaders. The company will be headquartered in the San Francisco, California, area and …

Read More